Tonix Pharmaceuticals to Showcase Tonmya™ Poster at the 2025 ACR Convergence

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Oct 20 2025

0mins

Source: Globenewswire

Presentation at ACR Convergence: Tonix Pharmaceuticals will present a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets) at the 2025 American College of Rheumatology Convergence, highlighting its effectiveness in reducing pain and its tolerability for fibromyalgia patients.
FDA Approval and Product Portfolio: Tonix has received FDA approval for Tonmya™, marking the first new prescription medicine for fibromyalgia in over 15 years, and has a diverse pipeline focusing on CNS disorders, immunology, and infectious diseases.
Clinical Development and Research: The company is also developing TNX-102 SL for acute stress reactions and major depressive disorder, alongside other investigational drugs targeting various health conditions, including autoimmune diseases and infectious threats.
Safety and Usage Information: Tonmya™ has specific contraindications and warnings, including risks of serotonin syndrome and potential fetal harm during pregnancy, emphasizing the need for careful patient monitoring and adherence to safety guidelines.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free